Anti-TNF-α therapy for uveitis: Behçet and beyond

Eye

Volumn 19, Issue 8, 2005, Pages 831-833

  Murray, P I ^a   Sivaraj, R R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CD4 ANTIGEN; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN P55; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

BEHCET DISEASE; BLINDNESS; CYTOKINE PRODUCTION; DISEASE CONTROL; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MACROPHAGE; MEDICAL LITERATURE; PROTEIN EXPRESSION; QUALITY OF LIFE; REMISSION; RETINA MACULA CYSTOID EDEMA; RETINA VASCULITIS; RETINITIS; SARCOIDOSIS; T LYMPHOCYTE; TREATMENT OUTCOME; TUBERCULOSIS; UVEITIS; UVEORETINITIS; VISUAL ACUITY;

EID: 23944465465     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6701792     Document Type: Editorial

References (25)

1. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Méndez-Fernández R, López-Abad C, Matilla M et al. Long-term treatment of refractory posterior uveitis with anti-TNFα (infliximab). Eye 2005; 19(8): 841-845.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
3. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
4. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193.
5. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004; 23: 617-637.
6. Avunduk MC, Avunduk AM, Oztekin E, Baltaci AK, Ozyazgan Y, Mogolkoc R. Etanercept treatment in the endotoxin-induced uveitis of rats. Exp Eye Res 2004; 79: 357-365.
7. Santos LM, Marcos MC, Gallardo GJM, Gomez VMA, Collantes EE, Ramirez CR et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001; 33: 251-255.
8. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411-1415.
9. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252-257.
10. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003; 121: 437-440.
11. Murphy CC, Greiner K, Plskova J, Duncan L, Frost A, Isaacs JD et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 2004; 122: 845-851.
12. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295-296.
13. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 2001; 358: 1644.
14. Triolo G, Vadalà M, Accardo-Palumbo A, Ferrante A, Ciccia F, Giardina E et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis 2002; 61: 560-561.
15. El-Shabrawi YG, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002; 109: 2342-2346.
16. Morris DS, Gavin MP, Sturrock RD. The effect of antitumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behcet' s disease. Adv Exp Med Biol 2003; 528: 557-559.
17. Giansanti F, Barbera ML, Vigili G, Pieri B, Emmi L, Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease. Eur J Ophthalmol 2004; 14: 445-448.
18. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003; 110: 1449-1453.
19. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111: 352-356.
20. Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, Fain O, LeHoang P, Piette JC. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 2004; 22(4 Suppl 34): S14-S16.
21. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004; 140: 404-406.
22. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362-1368.
23. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004; 138: 648-650.
24. Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behcet's disease. J Rheumatol 2004; 31: 1241-1243.
25. Murray PI. Idiopathic (autoimmune) sight-threatening uveitis. In: Wormald R, Smeeth L, Henshaw K (eds). Evidence-based Ophthalmology. BMJ Books: London, 2004, pp 167-173.